Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FOXM1
REST API REST API
Homo sapiens
FOXM1 is differentially expressed in 285 experiments: 98 organism parts: bone marrow, testis, ... (96 more);, 206 disease states: normal, control, ... (204 more);, 92 cell types 278 cell lines 30 compound treatments and 70 other conditions.
Synonyms trident, HFH-11, HNF-3, INS-1, FKHL16, MPHOSPH2, MPP2, TGT3
Orthologs FOXM1 (Gallus gallus)   Foxm1 (Mus musculus)   foxm1 (Danio rerio)   FOXM1 (Bos taurus)   ENSGALG00000019005 (Gallus gallus)   FHL1 (Saccharomyces cerevisiae)   ENSCING00000013449 (Ciona intestinalis)   Q4H3I0_CIOIN (Ciona intestinalis)   Foxm1 (Rattus norvegicus)   foxm1 (Xenopus laevis)   FOXM1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term pattern specification process, embryo development, DNA binding, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, cytoplasm, double-stranded DNA binding, regulation of cell proliferation, transcription, DNA-dependent, positive regulation of cell proliferation, DNA bending activity, protein domain specific binding, transcription from RNA polymerase II promoter, transcription factor binding, sequence-specific DNA binding, cell cycle, regulation of Ras protein signal transduction, positive regulation of transcription from RNA polymerase II promoter, tissue development, nucleus, transcription factor complex, regulation of cell growth, negative regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, vasculogenesis, negative regulation of stress-activated MAPK cascade, liver development, sequence-specific DNA binding transcription factor activity, negative regulation of cell aging, regulation of cell cycle arrest, regulation of sequence-specific DNA binding transcription factor activity, regulation of reactive oxygen species metabolic process, transcription regulatory region DNA binding, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity
InterPro Term TF_fork_head
UniProt Accession Q53Y49, A8K591, Q08050
Search EB-eye ENSG00000111206
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (35 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
GM15510
2
E-GEOD-19466, E-GEOD-22639
BT474
2
E-MEXP-440, E-MTAB-62
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
Daudi
2
E-GEOD-96, E-MTAB-37
MOLT4
2
E-MTAB-62, E-MTAB-37
272 more value(s).


Cell type

studied in E-GEOD-500, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, ... (39 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
endothelial cell
2
E-GEOD-3920, E-GEOD-19240
hematopoietic stem cell
2
E-MEXP-1403, E-MEXP-872
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
CD326negCD56+ cell
1
E-GEOD-21668
86 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-16363, ... (72 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-GEOD-2514, E-MTAB-62, E-MEXP-231
prostate carcinoma
3
E-GEOD-96, E-MEXP-2034, E-MTAB-62
control
1
3
E-GEOD-21912, E-GEOD-3185, E-GEOD-16363, E-GEOD-8121
Huntington's disease
2
E-GEOD-3790, E-AFMX-6
acute lymphoblastic leukemia
2
E-GEOD-96, E-MTAB-62
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
200 more value(s).


Compound treatment

studied in E-GEOD-7400, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-GEOD-5099, ... (20 experiments)

Factor Value U/D Experiments
Cxcl12
1
E-GEOD-7307
nocodazole
1
E-GEOD-6431
granulocyte-colony stimulating factor
1
E-GEOD-7400
M-CSF
1
E-GEOD-5099
TGF-Beta1
1
E-MEXP-2645
AMP
1
E-MEXP-2285
24 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-MEXP-958, ... (6 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-19665 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-22593, E-GEOD-18005, E-TABM-601, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-10315, E-GEOD-837, E-GEOD-1692, E-GEOD-20505, ... (16 experiments)

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-2748

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-GEOD-16363, ... (26 experiments)

Infection
studied in E-MEXP-1274

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-MEXP-1412, E-GEOD-1657, ... (9 experiments)

Population
studied in E-MTAB-197

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-MEXP-973, E-GEOD-19246, E-GEOD-19136, ... (7 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-3494, E-TABM-43, E-GEOD-1561, ... (8 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.421 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM